Table 3.
Parameters | ORR |
PFS |
OS |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariable analysis |
Multivariable analysis |
Univariable analysis |
Multivariable analysis |
Univariable analysis |
Multivariable analysis |
|||||||
ORb (95% CI) | P | ORc (95% CI) | P | HRd (95% CI) | P | HRe (95% CI) | P | HRd (95% CI) | P | HRe (95% CI) | P | |
Doubling pack-years | 1.20 (1.09 to 1.34) | <.001 | 1.21 (1.09 to 1.36) | <.001 | 0.91 (0.88 to 0.95) | <.001 | 0.92 (0.88 to 0.95) | <.001 | 0.95 (0.91 to 0.99) | .02 | 0.94 (0.90 to 0.99) | .01 |
Age | NA | NA | 1.01 (0.99 to 1.03) | .51 | NA | NA | 1.00 (0.99 to 1.00) | .23 | NA | NA | 1.00 (0.99 to 1.01) | .93 |
Male vs female | NA | NA | 0.74 (0.49 to 1.10) | .13 | NA | NA | 1.17 (0.99 to 1.39) | .06 | NA | NA | 1.22 (1.01 to 1.47) | .04 |
Squamous vs nonsquamous | NA | NA | 1.29 (0.70 to 2.31) | .41 | NA | NA | 1.05 (0.81 to 1.36) | .71 | NA | NA | 1.16 (0.88 to 1.54) | .30 |
ECOG PS | ||||||||||||
≥2 vs 0-1 | NA | NA | 0.30 (0.16 to 0.53) | <.001 | NA | NA | 2.03 (1.66 to 2.48) | <.001 | NA | NA | 2.99 (2.40 to 3.73) | <.001 |
Unknown vs 0-1 | NA | NA | 0.62 (0.03 to 4.61) | .68 | NA | NA | 0.77 (0.32 to 1.86) | .56 | NA | NA | 0.42 (0.10 to 1.68) | .22 |
PD-L1 TPS | ||||||||||||
≥50% vs negative | NA | NA | 4.14 (1.91 to 10.06) | <.001 | NA | NA | 0.54 (0.41 to 0.72) | <.001 | NA | NA | 0.63 (0.45 to 0.87) | .006 |
1%-49% vs negative | NA | NA | 1.48 (0.64 to 3.74) | .38 | NA | NA | 0.88 (0.67 to 1.17) | .39 | NA | NA | 0.97 (0.71 to 1.32) | .85 |
Unknown vs negative | NA | NA | 2.25 (1.02 to 5.50) | .06 | NA | NA | 0.79 (0.61 to 1.05) | .11 | NA | NA | 0.96 (0.71 to 1.28) | .77 |
2L+ vs 1 L treatment | NA | NA | 0.90 (0.57 to 1.43) | .65 | NA | NA | 1.06 (0.86 to 1.30) | .61 | NA | NA | 1.30 (1.02 to 1.65) | .04 |
All P values were 2-sided. CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group Performance Status; HR = hazard ratio; 1 L = first-line treatment setting; 2 L+ = second-line treatment setting and beyond; NA = not applicable; OR = odds ratio; ORR = objective response rate; OS = overall survival; PD-L1 TPS = programmed cell death ligand-1 tumor proportion score; PFS = progression-free survival.
Unadjusted OR of objective response.
OR of objective response adjusted for age, gender, histology, ECOG PS, PD-L1 TPS, and lines of treatment.
Unadjusted HR.
HR adjusted for age, gender, histology, ECOG PS, PD-L1 TPS, and lines of treatment.